-
MomentumOptionsTrading.com Weekly Wrap for 8/21/11
Sunday, August 21, 2011 - 10:49pm | 6010:40pm (EST) 1. Market Summary 2. Is Dendreon (DNDN) a Steal in the Low Teens? 3. Selling Puts on Stocks You Like Can Be Beneficial 4. Earnings 5. Weekly Wrap Portfolio Update 6. Week Ahead (To view the charts, please log into the Members Area and go to the Weekly Wrap Premium...
-
UPDATE: Seattle Genetics Announces FDA Accelerated Approval of ADCETRIS™ (Brentuximab Vedotin) for Two Indications
Friday, August 19, 2011 - 2:08pm | 171Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of ADCETRISTM (brentuximab vedotin) for two indications: (1) the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT...
-
Notable Call Options Activity in Momenta Pharmaceuticals
Friday, August 19, 2011 - 1:30pm | 82Shares of Momenta Pharmaceuticals (NASDAQ: MNTA) are higher on the session by 2.32%, currently trading at $16.34. The stock has been moving largely lower over the past two months and is currently trading below at the 50-day average. Options traders are focusing on calls today. A short while ago...
-
Notable Call Options Activity in Vical
Friday, August 19, 2011 - 1:12pm | 88Shares of Vical (NASDAQ: VICL) are higher on the session by 3.76%, currently trading at $3.59. The stock has been moving largely lower over the past two months and is currently trading below at the 50-day average. Options traders are focusing on calls today. A short while ago the March 2012 $2.50...
-
Notable Call Options Activity in Isis Pharmaceuticals
Friday, August 19, 2011 - 12:44pm | 84Shares of Isis Pharmaceuticals (NASDAQ: ISIS) are higher on the session by 2.50%, currently trading at $6.97. The stock has been moving largely lower over the past three months and is currently trading below at the 50-day average. Options traders are focusing on calls today. A short while ago the...
-
Cytokinetics Announces Phase I and Phase IIa Clinical Trial Results for Omecamtiv Mecarbil Published in the Journal Lancet
Friday, August 19, 2011 - 8:00am | 141Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the publication of results from two clinical trials of omecamtiv mecarbil, a novel cardiac myosin activator, in the August 20, 2011 issue of the journal Lancet. These two manuscripts present data regarding the safety, tolerability,...
-
Fast Money Picks For August 19th (PCG, TGT, AMGN)
Thursday, August 18, 2011 - 8:05pm | 143CNBC Fast Money's Brian Kelly said on the show that you should sell silver tomorrow. Guy Adami believes that PG&E Corporation (NYSE: PCG) should be bought on Friday. PG&E Corporation (PCG) gained 0.12% today, and it closed at $41.30. Karen Finerman still likes Target Corporation (NYSE:...
-
CEL-SCI Addresses Warning Letter in Regard to Statements on Its Corporate Website
Thursday, August 18, 2011 - 5:00pm | 197CEL-SCI Corporation (NYSE: CVM) announced today that it has received and responded to a Warning Letter issued to the Company by the Division of Drug Advertising Marketing and Compliance U.S. Food and Drug Administration regarding certain statements made about the Company's investigational therapy...
-
Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research Meeting
Thursday, August 18, 2011 - 4:14pm | 127Amgen (NASDAQ: AMGN) today announced that it will present data from several Prolia® (denosumab) studies, including eight year efficacy and safety data from a Phase 2 extension study in women with postmenopausal osteoporosis with low bone mineral density, at the 2011 American Society for Bone and...
-
Regeneron Blindsided By PDFUA Delay
Thursday, August 18, 2011 - 11:51am | 650Regeneron Pharmaceuticals (NASDAQ: REGN) has been informed by the FDA that the PDFUA date for its Eylea drug, a treatment for age-related macular degeneration, has been extended three months to November 18th, 2011. The agency made the decision as "a result of classifying responses to questions...
-
Tuesday's NASDAQ Top Gainers: Marshall Edwards, Renaissance Learning, Majesco Entertainment, Netlist
Thursday, August 18, 2011 - 11:02am | 478POINT ROBERTS, Aug. 17, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, reports on top percentage gainers on the NASDAQ for Aug. 16, 2011. Marshall Edwards, Inc. (NASDAQ: MSHL) was the biggest gainer on Nasdaq and soared 0.53 (38.41%) to $1.91 after...
-
Celsion Announces Approval of $1.2M New Jersey Economic Development Authority Incentive Grant
Thursday, August 18, 2011 - 9:35am | 93Celsion Corporation (NASDAQ: CLSN) announced today that the New Jersey Economic Development Authority has approved the Company's application for a Business Employment Incentive Program (BEIP) grant. BEIP grants are available to economically viable expanding or relocating businesses that create jobs...
-
Cardium Announces Receipt of $1.1 Million in Funds from Philips' Acquisition of Innercool Therapies
Thursday, August 18, 2011 - 9:01am | 83Cardium Therapeutics (NYSE: CXM) today reported that it had received funds corresponding to the final $1.1 million payment from Royal Philips Electronics in connection with Philips' acquisition of Innercool Therapies from Cardium. The release of funds from restricted cash represents the receipt of...
-
DARA BioSciences Receives Fast Track Designation From the U.S. FDA for KRN5500 for the Treatment of Chemotherapy-Induced Neuropathic Pain in Patients With Cancer
Thursday, August 18, 2011 - 9:00am | 229DARA BioSciences, Inc. (Nasdaq: DARA) announced today that its investigational drug KRN5500 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of chemotherapy-induced neuropathic pain in patients with cancer. The FDA's Fast Track program is...
-
DARA BioSciences Receives Fast Track Designation From the U.S. FDA for KRN5500 for the Treatment of Chemotherapy-Induced Neuropathic Pain in Patients With Cancer
Thursday, August 18, 2011 - 9:00am | 229DARA BioSciences, Inc. (Nasdaq: DARA) announced today that its investigational drug KRN5500 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of chemotherapy-induced neuropathic pain in patients with cancer. The FDA's Fast Track program is...